



## J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road, Worli, Mumbai 400 030.  
Corporate Office : Energy IT Park, Unit A2, 3<sup>rd</sup> Floor, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.  
Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334  
CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30<sup>TH</sup> SEPTEMBER, 2018

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Half Year ended		Year ended
		30-09-2018	30-06-2018	30-09-2017	30-09-2018	30-09-2017	31-03-2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Revenue from Operations</b>	40,427.40	36,597.17	34,731.92	77,024.57	63,115.70	1,25,473.42
2	Other Income	810.54	111.72	956.89	922.26	1,884.07	3,525.53
3	<b>Total Income ( 1+2)</b>	<b>41,237.94</b>	<b>36,708.89</b>	<b>35,688.81</b>	<b>77,946.83</b>	<b>64,999.77</b>	<b>1,28,998.95</b>
4	<b>Expenses</b>						
	a. Cost of materials consumed	11,451.18	11,100.08	8,030.15	22,551.26	16,848.97	38,701.68
	b. Purchases of stock-in-trade	2,907.92	2,469.39	3,861.00	5,377.31	6,297.92	9,304.46
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	110.36	(409.59)	1,931.15	(299.23)	1,796.91	(38.81)
	d. Employee benefit expenses	6,626.02	5,937.70	5,299.79	12,563.72	10,881.96	21,730.93
	e. Finance Costs	71.57	127.23	106.05	198.80	185.17	341.36
	f. Depreciation and amortization expense	1,446.62	1,446.52	1,432.71	2,893.14	2,865.55	5,594.85
	g. Other Expenses	11,119.98	10,089.44	8,233.05	21,209.42	16,806.39	35,460.18
	<b>Total Expenses (4)</b>	<b>33,733.65</b>	<b>30,760.77</b>	<b>28,893.90</b>	<b>64,494.42</b>	<b>55,682.87</b>	<b>1,11,094.65</b>
5	<b>Profit before Tax (3-4)</b>	<b>7,504.29</b>	<b>5,948.12</b>	<b>6,794.91</b>	<b>13,452.41</b>	<b>9,316.90</b>	<b>17,904.30</b>
6	Tax expenses	2,360.28	1,741.07	1,622.49	4,101.35	2,107.75	5,104.16
7	<b>Net Profit/(Loss) after Tax (5-6)</b>	<b>5,144.01</b>	<b>4,207.05</b>	<b>5,172.42</b>	<b>9,351.06</b>	<b>7,209.15</b>	<b>12,800.14</b>
8	Other Comprehensive Income ( net of Tax)	(61.81)	(61.80)	(13.08)	(123.61)	(80.69)	(241.63)
9	<b>Total Comprehensive Income after Tax (7+8)</b>	<b>5,082.20</b>	<b>4,145.25</b>	<b>5,159.34</b>	<b>9,227.45</b>	<b>7,128.46</b>	<b>12,558.51</b>
10	<b>(i) Earning per share(EPS) (of Rs. 2/- each not annualised)</b>						
	(1) Basic	6.16	5.03	6.16	11.19	8.59	15.24
	(2) Diluted	6.16	5.03	6.16	11.19	8.59	15.24

#### NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meeting held on November 2, 2018.
- The auditors have carried out limited review of the financial results for the quarter and half –year ended on September 30, 2018 and they have not expressed modified opinion.
- The Company has one reportable segment viz. Pharmaceuticals.
- The amount of damage caused due to explosion/fire on July 6, 2018 at Company's API unit at Panoli, Gujarat is being assessed by the Company with the help of technical experts to determine the exact loss of assets. In the interim, the Company has put up a claim for an amount of Rs. 26.07 crores with insurance company based on estimated cost of replacement. The Company believes that the final loss, when determined on due completion of process, will not materially impact the financials as the same would be covered by insurance claim. Further, the estimate of loss of sales of Rs. 5 crores and additional cost of about Rs. 2 crores on procurement of certain APIs from outside during the current financial year due to this incident remain the same. The Company does not consider this impact as material keeping in view the size of its operations.
- The dividend of Rs. 2 per equity share of FV Rs.2 declared by the members at the annual general meeting held on September 4, 2018 has been paid on September 6, 2018. This together with dividend distribution tax absorbed Rs. 20.15 crores.
- The Company has completed the buy-back of 33,33,333 equity shares of Rs. 2 each @ Rs. 390 per share on November 1, 2018. Post this buy-back, the share capital of the Company would reduce to Rs. 16,04,73,284 divided into 8,02,36,642 equity shares of Rs. 2 each.
- Post applicability of Goods and Service Tax (GST) with effect from July 1, 2017, the sales and services which are subjected to GST are disclosed net of GST. Accordingly, the sales and services for the half year ended September 30, 2018 is not comparable with the previous corresponding half year as the figures for the previous half year was inclusive of excise duty.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.
- The statement of assets and liabilities as at September 30, 2018 is as under:

(Rs. in lakhs)

Particulars	As at	As at
	September 30,2018	March 31,2018
<b>ASSETS</b>		
<b>(I) Non-current assets</b>		
(a) Property, Plant and Equipment	56,327.25	55,993.76
(b) Capital work-in-progress	664.28	1,740.23
(c) Other Intangible assets	958.05	997.01
(d) Financial Assets		
(i) Investments	22,344.30	18,292.47
(ii) Trade receivables	-	-
(iii) Loans	362.37	332.67
(iv) Others	323.18	344.10
(e) Other non-current assets	418.32	426.08
<b>TOTAL non current assets</b>	<b>81,397.75</b>	<b>78,126.32</b>

<b>(II)</b>	<b>Current assets</b>		
	(a) Inventories	18,998.76	17,581.44
	(b) Financial Assets		
	(i) Investments	41,405.45	38,376.60
	(ii) Trade receivables	33,355.55	30,054.05
	(iii) Cash and cash equivalents	1,223.85	1,495.33
	(iv) Loans	21.24	16.38
	(v) Others	178.89	78.05
	(c) Current Tax Assets (Net)	142.99	806.28
	(d) Other current assets	9,303.66	10,131.15
	<b>TOTAL current assets</b>	<b>1,04,630.39</b>	<b>98,539.28</b>
	<b>Total Assets</b>	<b>1,86,028.14</b>	<b>1,76,665.60</b>
	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	(a) Equity Share capital	1,671.40	1,671.40
	(b) Other Equity	1,50,879.90	1,43,667.41
	<b>Total Equity</b>	<b>1,52,551.30</b>	<b>1,45,338.81</b>
	<b>LIABILITIES</b>		
<b>(I)</b>	<b>Non-current liabilities</b>		
	(a) Provisions	1,145.37	967.36
	(b) Deferred tax liabilities (Net)	5,739.58	4,970.15
	(c) Other non-current liabilities	208.00	360.01
	<b>TOTAL non current Liabilities</b>	<b>7,092.95</b>	<b>6,297.52</b>
<b>(II)</b>	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	4,288.66	2,847.62
	(ii) Trade payables		
	A) Dues to Micro and Small Enterprises	37.59	74.50
	B) Due to Other Creditors	9,281.89	9,947.60
	Total Trade Payables	9,319.48	10,022.10
	(iii) Other financial liabilities	9,889.25	10,119.56
	(b) Other current liabilities	1,743.27	1,148.76
	(c) Provisions	1,143.23	891.23
	(d) Current Tax Liabilities (Net)	-	-
	<b>TOTAL Current Liabilities</b>	<b>26,383.89</b>	<b>25,029.27</b>
	<b>Total Equity and Liabilities</b>	<b>1,86,028.14</b>	<b>1,76,665.60</b>

For J.B. Chemicals & Pharmaceuticals Ltd.



J.B. Mody  
Chairman & Managing Director

Place : Mumbai  
Date : 02/11/2018